Equities analysts expect Mediwound Ltd (NASDAQ:MDWD) to post $4.79 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Mediwound’s earnings, with the highest sales estimate coming in at $5.17 million and the lowest estimate coming in at $4.40 million. Mediwound reported sales of $20.75 million during the same quarter last year, which indicates a negative year over year growth rate of 76.9%. The company is expected to issue its next earnings results before the market opens on Thursday, August 6th.
According to Zacks, analysts expect that Mediwound will report full year sales of $21.74 million for the current financial year, with estimates ranging from $21.60 million to $21.88 million. For the next financial year, analysts anticipate that the firm will post sales of $32.05 million, with estimates ranging from $30.99 million to $33.10 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Mediwound.
Mediwound (NASDAQ:MDWD) last issued its earnings results on Wednesday, May 20th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.05. The company had revenue of $4.44 million for the quarter, compared to analyst estimates of $4.25 million. Mediwound had a net margin of 18.46% and a negative return on equity of 75.91%.
A number of analysts recently weighed in on MDWD shares. Oppenheimer reiterated a “buy” rating and issued a $7.00 price target on shares of Mediwound in a research report on Tuesday, June 30th. ValuEngine downgraded shares of Mediwound from a “buy” rating to a “hold” rating in a report on Tuesday, July 7th. HC Wainwright restated a “buy” rating and set a $5.50 target price on shares of Mediwound in a report on Wednesday, July 1st. Finally, Zacks Investment Research upgraded shares of Mediwound from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a report on Saturday, June 20th.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Thomasville National Bank acquired a new stake in shares of Mediwound in the second quarter valued at approximately $67,000. Wells Fargo & Company MN raised its holdings in shares of Mediwound by 15.8% in the first quarter. Wells Fargo & Company MN now owns 219,386 shares of the biopharmaceutical company’s stock valued at $345,000 after purchasing an additional 29,911 shares during the last quarter. Fortis Advisors LLC acquired a new stake in shares of Mediwound in the first quarter valued at approximately $108,000. Sargent Investment Group LLC raised its holdings in shares of Mediwound by 51.5% in the first quarter. Sargent Investment Group LLC now owns 117,400 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 39,900 shares during the last quarter. Finally, Acadian Asset Management LLC raised its holdings in shares of Mediwound by 136.4% in the first quarter. Acadian Asset Management LLC now owns 130,072 shares of the biopharmaceutical company’s stock valued at $205,000 after purchasing an additional 75,045 shares during the last quarter. Institutional investors own 22.93% of the company’s stock.
Shares of NASDAQ MDWD opened at $3.92 on Monday. The firm has a market capitalization of $106.94 million, a PE ratio of 16.33 and a beta of 1.52. The company has a current ratio of 3.08, a quick ratio of 2.89 and a debt-to-equity ratio of 0.15. Mediwound has a 1 year low of $1.44 and a 1 year high of $4.44. The firm’s 50-day moving average is $3.23 and its 200-day moving average is $2.52.
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Further Reading: How can you know how many shares are floating?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.